AstraZeneca completes Zurampic deal with Ironwood

Drugmaker AstraZeneca continued its charge of licensing its Zurampic (lesinurad) drug on Friday, with the company announcing it has completed its licensing agreement with Ironwood Pharmaceuticals for the exclusive United States rights to the drug.

AstraZeneca

9,990.00p

15:45 15/11/24

-2.93%

-302.00p

FTSE 100

8,060.61

15:45 15/11/24

n/a

FTSE 350

4,453.56

15:45 15/11/24

n/a

FTSE All-Share

4,411.85

15:45 15/11/24

n/a

Pharmaceuticals & Biotechnology

19,259.77

15:45 15/11/24

-2.70%

-535.19

The FTSE 100 firm said the agreement also covered a fixed-dose combination of lesinurad and allopurinol.

Zurampic is already approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout.

“The fixed-dose combination will be submitted for regulatory review in the second half of 2016,” AstraZeneca’s board confirmed in a statement.

It came a day after AstraZeneca revealed it has entered into a licensing agreement with German drug firm Grünenthal GmbH for the exclusive rights to Zurampic in Europe and Latin America.